Abstract:【Objective】To investigate the efficacy of dorsal root ganglion pulsed radiofrequency combined with pregabalin in the treatment of postherpetic neuralgia (PHN) and identify related influencing factors.【Methods】A total of 90 patients with PHN, who were treated at the Third People's Hospital of Nantong between May 2020 and May 2023, were enrolled. All patients received dorsal root ganglion pulsed radiofrequency combined with pregabalin treatment. Pain intensity was assessed before and after treatment using the Visual Analog Scale (VAS), and inflammatory markers including calcitonin gene-related peptide (CGRP), β-endorphin (β-EP), and prostaglandin E2 (PGE2) were measured as well. After 6 months of follow-up, patients were divided into the effective group and the ineffective groups based on the treatment outcome. Clinical data were collected, and multivariate Logistic regression analysis was performed to determine the factors influencing the treatment efficacy.【Results】After treatment, VAS scores significantly decreased (P<0.05). Levels of CGRP and PGE2 were lower, while β-EP levels were higher compared to baseline before treatment (P<0.05). There were significant differences between the two groups in terms of age, disease duration, diabetes, antiviral treatment, and the duration of analgesic use (P<0.05). Multivariate analysis showed that age >65 years, disease duration >6 months, diabetes, and prolonged analgesic use (>2 weeks) were risk factors affecting treatment efficacy (P<0.05).【Conclusion】Dorsal root ganglion pulsed radiofrequency combined with pregabalin significantly alleviates pain and reduces inflammatory markers in patients with PHN. Key risk factors influencing treatment efficacy include age >65 years, disease duration >6 months, diabetes, and prolonged use of analgesics for more than 2 weeks.
钱志强, 李春明. 背根神经节脉冲射频联合普瑞巴林治疗带状疱疹性神经痛患者疗效及影响因素[J]. 医学临床研究, 2025, 42(2): 239-242.
QIAN Zhiqiang, LI Chunming. Efficacy and Influencing Factors of Dorsal Root Ganglion Pulsed Radiofrequency Combined with Pregabalin in the Treatment of Postherpetic Neuralgia. JOURNAL OF CLINICAL RESEARCH, 2025, 42(2): 239-242.